Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03143153 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 970
- Enrollment target
NCT03143153 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 970 participants.
The verdict
NCT03143153, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 970 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare how long subjects with esophageal cancer live overall or live without disease progression after receiving nivolumab and ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin
Interventions
- DRUG Cisplatin
- DRUG Fluorouracil
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 970 participants |
| Start Date | 2017-06-29 |
| Est. Completion | 2025-01-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03143153
The ClinicalTrials.gov registry entry for NCT03143153 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 970 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT03143153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03143153 about?
NCT03143153 is a clinical study titled "A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin". The main purpose of this study is to compare how long subjects with esophageal cancer live overall or live without disease progression after receiving nivolumab and ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin
What is the current status of trial NCT03143153?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 970 participants. The study started on 2017-06-29. Estimated completion is 2025-01-13.
What interventions are being tested in trial NCT03143153?
The interventions under investigation include: Cisplatin (DRUG), Fluorouracil (DRUG), Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03143153?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.